T Cell News and Research

Latest T Cell News and Research

Illumina launches MicroRNA assay for gene expression profiling

Illumina, Inc. today launched a MicroRNA Assay for Gene Expression profiling. Priced at $95 per sample, this assay is the only solution available to allow rapid and reproducible miRNA expression profiling at a price less than half that of other commercially available methods.

From Illumina, Inc. 22 Oct 2007

Stem cells to treat damaged eyes and a rare skin disorder

Doctors and scientists in Italy have shown how stem cells can be used to treat damaged eyes and, in combination with gene therapy, a rare and debilitating skin disease.

22 Oct 2007

Experts warn women about experimental fertility options

The American Society for Reproductive Medicine (ASRM) has warned women that two experimental fertility procedures currently being offered remain unproven.

22 Oct 2007

Brain mechanism may help some cope better in stressful situations

According to researchers in the U.S. a mechanism found in some people's brain could be the key to them staying relaxed in stressful situations.

22 Oct 2007

Ubiquitin builds up an immune response

Ubiquitin is a small protein, which can be attached to other cellular proteins, a process known as ubiquitination.

22 Oct 2007

GenVec receives extra funding for adenovector-based HIV vaccines program

GenVec, Inc. has announced that the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has executed its sixth option period (year seven) under its multi-year collaboration with GenVec to develop and manufacture novel adenovector-based HIV vaccines.

22 Oct 2007

Bacteria use plant defence for genetic modification

Bacteria that cause tumours in plants modify plant genomes by skilfully exploiting the plants' first line of defence.

22 Oct 2007

Smurfs a major cause of osteoarthritis

A new clinical trial seeks to predict who is most likely to experience osteoarthritis, and to test whether an experimental treatment can prevent it altogether.

19 Oct 2007

West Nile virus' spread through nerve cells linked to serious complication

Scientists believe they have found an explanation for a puzzling and serious complication of West Nile virus infection.

19 Oct 2007

Transgenics sped up

A new method of constructing artificial plant chromosomes from small rings of naturally occurring plant DNA can be used to transport multiple genes at once into embryonic plants where they are expressed, duplicated as plant cells divide, and passed on to the next generation -- a long-term goal for those interested in improving agricultural productivity.

19 Oct 2007

Why some succumb to stress - new brain mechanism identified

Results of a new study may one day help scientists learn how to enhance a naturally occurring mechanism in the brain that promotes resilience to psychological stress.

19 Oct 2007

Researcher identify specific cell that causes eye cancer, disproving long-held theory

Investigators at St. Jude Children's Research Hospital have identified the cell that gives rise to the eye cancer retinoblastoma, disproving a long-standing principle of nerve growth and development.

19 Oct 2007

New pathway identified by which cancer cells grow and survive

Cancerous tumors are wildly unfavorable environments. Struggling for oxygen and nutrients while being bombarded by the body's defense systems, tumor cells in fact require sophisticated adaptations to survive and grow.

19 Oct 2007

Preventing tuberculosis reactivation

Tuberculosis (TB) is the leading cause of death due to infectious disease in the world today.

19 Oct 2007

New links in the cystic fibrosis chain uncover potential therapeutics

Cystic fibrosis (CF) is an inherited disease caused by mutations in the CFTR gene.

19 Oct 2007

Mice offer clues to the roots of human resilience

When faced with adversity, some people succumb to debilitating psychological diseases including posttraumatic stress disorder and depression, while others are able to remain remarkably optimistic.

19 Oct 2007

Lilly and MacroGenics to develop and commercialize teplizumab

Eli Lilly and Company and MacroGenics, Inc. have announced that the two companies have entered into a global strategic alliance to develop and commercialize teplizumab, a humanized anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules for use in the treatment of autoimmune diseases.

19 Oct 2007